Table 3 Asthma control and QoL at baseline and after benralizumab treatment initiation

Lung function

 Pre-BD FEV₁ (mL), N = 10

  Mean (SD)

1,827 (505.9)

1,982 (459.9)

  Difference, mean (SD)

155 (430.4)

  p-value*

0.284

 Pre-BD FEV₁ (%), N = 10

  Mean (SD)

63 (18.8)

68.9 (20.7)

  Difference, mean (SD)

5.8 (17.3)

  p-value*

0.314

 Pre-BD FEV₁/FVC (%), N = 10

  Mean (SD)

59.8 (9.9)

56.2 (24.2)

  Difference, mean (SD)

− 3.6 (20)

  p-value*

0.441

 Post-BD FEV₁ (mL), N = 9

  Mean (SD)

2,093.3 (995.8)

2,350 (1,062.9)

  Difference, mean (SD)

256.7 (400.6)

  p-value*

0.091

 Post-BD FEV₁ (%), N = 9

  Mean (SD)

66.2 (22.1)

73.5 (24.3)

  Difference, mean (SD)

7.3 (13.6)

  p-value*

0.147

 Post-BD FEV₁/FVC (%), N = 9

  Mean (SD)

65.2 (11.8)

67.4 (12.5)

  Difference, mean (SD)

2.2 (5.8)

  p-value*

0.291

 Blood eosinophil count (cells/μL), N = 13

  Mean (SD)

490 (353.9)

0.8 (2.8)

  Difference, mean (SD)

− 489.2 (354.4)

  p-value*

0.002

 OCS

N = 27

N = 19

  OCS-dependent, n (%)

24 (88.9)

15 (78.9)

  OCS dose reduction ≥ 50%, n (%)

6 (31.6)^a

  Oral prednisone (mg/day), N = 15

   Mean (SD)

15.1 (15.8)

21.8 (18.6)

   Difference, mean (SD)

6.7 (2.8)

   p-value*

0.144

 ACT, N = 15

  Mean (SD)

14.8 (6.8)

18.1 (6.3)

  Difference, mean (SD)

3.3 (6.8)

  p-value*

0.079

  Clinically meaningful difference (≥ 3), n (%)

9 (60)

 miniAQLQ, N = 5

  Mean (SD)

3.6 (0.8)

4.7 (1.5)

  Difference, mean (SD)

1.2 (1.9)

  p-value*

0.236

  Clinically meaningful difference (≥ 0.5), n(%)

2 (40)